dc.contributor.author |
Christ, AN |
en |
dc.contributor.author |
Labzin, L |
en |
dc.contributor.author |
Bourne, GT |
en |
dc.contributor.author |
Fukunishi, H |
en |
dc.contributor.author |
Weber, JE |
en |
dc.contributor.author |
Sweet, MJ |
en |
dc.contributor.author |
Smythe, ML |
en |
dc.contributor.author |
Flanagan, Jack |
en |
dc.date.accessioned |
2012-05-23T00:25:04Z |
en |
dc.date.issued |
2010-08-12 |
en |
dc.identifier.citation |
OURNAL OF MEDICINAL CHEMISTRY 53(15):5536-5548 12 Aug 2010 |
en |
dc.identifier.issn |
0022-2623 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/18157 |
en |
dc.description.abstract |
The hematopoietic prostaglandin D-2 synthase has a proinflammatory effect in a range of diseases, including allergic asthma, where its product prostaglandin D2 (PGD(2)) has a role in regulating many of the hallmark disease characteristics. Here we describe the development and characterization of a novel series of hematopoietic prostaglandin D2 synthase inhibitors with potency similar to that of known inhibitors. Compounds N-benzhydryl-5-(3-hydroxyphenyl)thiophene-2-carboxamide (compound 8) and N-(1-amino-1-oxo-3-phenylpropan-2-yl)-6-(thiophen-2-yl)nicotinamide (compound 34) demonstrated low micromolar potency in the inhibition of the purified enzyme, while only 34 reduced Toll-like receptor (TLR) inducible PG D2 production in both mouse primary bone marrow-derived macrophages and the human megakaryocytic cell line MEG-01S. Importantly, 34 demonstrated a greater selectivity for inhibition of PGD2 synthesis versus other eicosanoids that lie downstream of PGH(2) (PGE(2), and markers of prostacyclin (6-keto PGF(1 alpha)) and thromboxane (TXB2)) when compared to the known inhibitors HQL-79 (compound 1) and 2-phenyl-5-(1H-pyrazol-3-yl)thiazole (compound 2). Compound 34 therefore represents a selective hematopoietic prostaglandin D2 synthase inhibitor. |
en |
dc.language |
English |
en |
dc.publisher |
AMER CHEMICAL SOC |
en |
dc.relation.ispartofseries |
Journal of Medicinal Chemistry |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0022-2623/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Science & Technology |
en |
dc.subject |
Life Sciences & Biomedicine |
en |
dc.subject |
Chemistry, Medicinal |
en |
dc.subject |
Pharmacology & Pharmacy |
en |
dc.subject |
GLUTATHIONE-S-TRANSFERASE |
en |
dc.subject |
ANTIALLERGIC DRUG HQL-79 |
en |
dc.subject |
SAFETY-CATCH LINKER |
en |
dc.subject |
CATALYTIC-PROPERTIES |
en |
dc.subject |
PRIVILEGED SUBSTRUCTURES |
en |
dc.subject |
RECEPTOR ANTAGONIST |
en |
dc.subject |
MEDIATOR RELEASE |
en |
dc.subject |
D SYNTHETASE |
en |
dc.subject |
MAST-CELLS |
en |
dc.subject |
ALLERGEN |
en |
dc.title |
Development and Characterization of New Inhibitors of the Human and Mouse Hematopoietic Prostaglandin D-2 Synthases |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1021/jm100194a |
en |
pubs.issue |
15 |
en |
pubs.begin-page |
5536 |
en |
pubs.volume |
53 |
en |
dc.rights.holder |
Copyright: AMER CHEMICAL SOC |
en |
dc.identifier.pmid |
20684598 |
en |
pubs.end-page |
5548 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
119956 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Pharmacology |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2012-05-23 |
en |
pubs.dimensions-id |
20684598 |
en |